Chief Medical Advisor

Augmentiqs, a medical device company focused on improving the pathology workflow and disease diagnosis via innovative digital pathology technologies, has announced today that Dr. Abraham Nyska has joined the company as the Chief Medical Advisor and member of Augmentiq’s Scientific Advisory Board. Dr. Nyska practices toxicologic pathology, with nearly 40 years’ experience in evaluation and pre-clinical risk assessment of chemicals, drugs, medical devices and stem cells. Dr. Nyska is also a visiting full professor of pathology at the Sackler School of Medicine at Tel-Aviv University.

“We are pleased and honored to have Dr. Nyska as our Chief Medical Advisor and member of our Scientific Advisory Board," said Gabe Siegel, CEO and Co-founder of Augmentiqs. "Dr. Nyska brings invaluable expertise in the field of toxicologic pathology, including 10 years as a staff scientist and expert at the American National Toxicology Program (NTP) at the National Institute of Health, followed by another 8 years as an NTP consultant. We are certain that Dr. Nyska will bring incredibly value to Augmentiqs and its shareholders as the company moves forward."

Dr. Nyska completed his Doctorate of Veterinary Medicine at the University of Bologna, Italy, and performed post-graduate studies at Israel’s Kimron Veterinary Institute, while specializing in Toxicologic Pathology at the Laboratories of Life Science Research in England. Dr. Nyska also earned his Diplomate from the European College of Veterinary Pathology. Dr. Nyska serves as an Associate Editor of the journal “Toxicologic Pathology”. He has strong research-oriented attitude and vast collaboration with top federal research institutes (i.e., NIH, EPA) and academic institutes, with more than 410 publications in peer reviewed journals.

Prof. Nyska is a consultant in Toxicologic Pathology to pharmaceutical companies, CRO’s, and government agencies in Israel, Europe, India and the USA. Having twice earned the highly valued NIH Director Award for his knowledge and dedication, Augmentiqs is certain that his involvement will ensure the company’s success.


Posted on

April 22, 2016

Submit a Comment

Your email address will not be published. Required fields are marked *